Connor Clark & Lunn Investment Management Ltd. Acquires New Position in Relay Therapeutics, Inc. $RLAY

Posted by Brian Himes on Aug 26th, 2026

Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 961,702 shares of the company’s stock, valued at approximately $17,993,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Alphabet Inc. acquired a new stake in shares of Relay Therapeutics during the 2nd quarter valued at approximately $26,382,000. California State Teachers Retirement System grew its holdings in shares of Relay Therapeutics by 47.9% in the 1st quarter. California State Teachers Retirement System now owns 174,099 shares of the company’s stock worth $1,732,000 after acquiring an additional 56,422 shares during the period. Persistent Asset Partners Ltd purchased a new position in Relay Therapeutics in the 2nd quarter valued at approximately $1,323,000. Bank of America Corp DE increased its stake in Relay Therapeutics by 86.1% in the 1st quarter. Bank of America Corp DE now owns 1,937,695 shares of the company’s stock valued at $19,280,000 after purchasing an additional 896,746 shares in the last quarter. Finally, Sanctuary Advisors LLC acquired a new position in Relay Therapeutics during the fourth quarter worth $1,203,000. 96.98% of the stock is currently owned by institutional investors and hedge funds.

Relay Therapeutics Stock Up 4.1%

Shares of RLAY opened at $20.57 on Wednesday. Relay Therapeutics, Inc. has a fifty-two week low of $3.44 and a fifty-two week high of $21.27. The company’s fifty day moving average is $19.07 and its two-hundred day moving average is $14.56. The firm has a market cap of $4.51 billion, a PE ratio of -13.10 and a beta of 1.69.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.02). The company had revenue of $0.35 million during the quarter, compared to analyst estimates of $0.96 million. As a group, equities research analysts anticipate that Relay Therapeutics, Inc. will post -1.61 earnings per share for the current year.

Analyst Ratings Changes

Several research firms recently commented on RLAY. Zacks Research upgraded shares of Relay Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. JonesTrading upgraded Relay Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, May 19th. Wells Fargo & Company upped their target price on Relay Therapeutics from $17.00 to $21.00 and gave the company an “overweight” rating in a research note on Tuesday, April 28th. Oppenheimer increased their target price on Relay Therapeutics from $14.00 to $18.00 and gave the stock an “outperform” rating in a research report on Tuesday, April 28th. Finally, Guggenheim reissued a “buy” rating on shares of Relay Therapeutics in a research note on Friday, August 7th. Two analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Relay Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $25.92.

Check Out Our Latest Stock Analysis on RLAY

Insider Transactions at Relay Therapeutics

In other news, CEO Sanjiv Patel sold 48,199 shares of Relay Therapeutics stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $19.58, for a total value of $943,736.42. Following the transaction, the chief executive officer directly owned 615,898 shares of the company’s stock, valued at $12,059,282.84. The trade was a 7.26% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Peter Rahmer sold 50,000 shares of the business’s stock in a transaction dated Tuesday, June 30th. The stock was sold at an average price of $19.09, for a total value of $954,500.00. Following the sale, the insider owned 225,857 shares of the company’s stock, valued at $4,311,610.13. The trade was a 18.13% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 409,639 shares of company stock valued at $7,233,399. 5.04% of the stock is owned by company insiders.

About Relay Therapeutics

(Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.